** Drug developer BioAge Labs' BIOA.O shares rise ~10% to $4.52
** BIOA says it is collaborating with Swiss drugmaker Novartis NOVN.S to find new drug targets for age-related diseases
** BIOA will receive $20 mln upfront and up to $530 mln in milestone payments
** Including session's moves, stock down 80% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。